Prof. Jiří Mayer

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2021

• Romzova, M; Smitalova, D; Hynst, J; Tom, N; Loja, T; Herudkova, Z; Jurcek, T; Stejskal, L; Zackova, D; Mayer, J; Racil, Z; Culen, M, 2021: Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up. BRITISH JOURNAL OF HAEMATOLOGY 194(3), p. 604 - 612, doi: 10.1111/bjh.17659
• Hrabovsky, S; Vrzalova, Z; Stika, J; Jelinkova, H; Jarosova, M; Navrkalova, V; Martenek, J; Folber, F; Salek, C; Horacek, JM; Pospisilova, S; Mayer, J; Doubek, M, 2021: Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on BCR-ABL1-like subtype. ACTA ONCOLOGICA 60(6), p. 760 - 770, doi: 10.1080/0284186X.2021.1900908
• Folta, A; Jurcek, T; Kubesova, B; Zackova, D; Semerad, L; Mayer, J; Jeziskova, I, 2021: Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients. LEUKEMIA & LYMPHOMA 62(5), p. 1239 - 1242, doi: 10.1080/10428194.2020.1861274

2020

• Weinbergerova, B; Kabut, T; Kocmanova, I; Lengerova, M; Pospisil, Z; Kral, Z; Mayer, J, 2020: Bronchoalveolar lavage fluid and serum 1,3-beta-d-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance. SCIENTIFIC REPORTS 10(1), doi: 10.1038/s41598-020-75132-3
• Robesova, B; Drncova, M; Folta, A; Krejci, M; Folber, F; Sustkova, Z; Mayer, J; Jeziskova, I, 2020: Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR. BONE MARROW TRANSPLANTATION 55(6), p. 1021 - 1022, doi: 10.1038/s41409-020-0938-x
• Trizuljak, J; Petruchova, T; Blahakova, I; Vrzalova, Z; Horinova, V; Doubkova, M; Michalka, J; Mayer, J; Pospisilova, S; Doubek, M, 2020: Diagnosis of Bloom Syndrome in a Patient with Short Stature, Recurrence of Malignant Lymphoma, and Consanguineous Origin. MOLECULAR SYNDROMOLOGY 11(2), p. 73 - 82, doi: 10.1159/000507006
• Trizuljak, J; Sperr, WR; Nekvindova, L; Elberink, HO; Gleixner, KV; Gorska, A; Lange, M; Hartmann, K; Illerhaus, A; Bonifacio, M; Perkins, C; Elena, C; Malcovati, L; Fortina, AB; Shoumariyeh, K; Jawhar, M; Zanotti, R; Bonadonna, P; Caroppo, F; Zink, A; Triggiani, M; Parente, R; von Bubnoff, N; Yavuz, AS; Hagglund, H; Mattsson, M; Panse, J; Jakel, N; Kilbertus, A; Hermine, O; Arock, M; Fuchs, D; Sabato, V; Brockow, K; Bretterklieber, A; Niedoszytko, M; van Anrooij, B; Reiter, A; Gotlib, J; Kluin-Nelemans, HC; Mayer, J; Doubek, M; Valent, P, 2020: Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. ALLERGY 75(8), p. 1927 - 1938, doi: 10.1111/all.14248
• Kozlova, V; Ledererova, A; Ladungova, A; Peschelova, H; Janovska, P; Slusarczyk, A; Domagala, J; Kopcil, P; Vakulova, V; Oppelt, J; Bryja, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2020: CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. PLOS ONE 15(3), doi: 10.1371/journal.pone.0229170
• Mancikova, V; Peschelova, H; Kozlova, V; Ledererova, A; Ladungova, A; Verner, J; Loja, T; Folber, F; Mayer, J; Pospisilova, S; Smida, M, 2020: Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. JOURNAL FOR IMMUNOTHERAPY OF CANCER 8(1), doi: 10.1136/jitc-2019-000471
• Malcikova, J; Pavlova, S; Vonkova, B; Kotaskova, J; Radova, L; Plevova, K; Zenatova, M; Hynst, J; Dvorackova, B; Panovska, A; Brychtova, Y; Tichy, B; Navrkalova, V; Pal, K; Mayer, J; Doubek, M; Pospisilova, S, 2020: Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. LEUKEMIA & LYMPHOMA 61, p. 222 - 224
• Romzova, M; Smitalova, D; Tom, N; Jurcek, T; Culen, M; Zackova, D; Mayer, J; Racil, Z, 2020: Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia. BRITISH JOURNAL OF HAEMATOLOGY , doi: 10.1111/bjh.16382

2019

• Folta, A; Culen, M; Jeziskova, I; Herudkova, Z; Tom, N; Hlubinkova, T; Janeckova, V; Durinikova, A; Vydra, J; Semerad, L; Dvorakova, D; Remesova, H; Cerovska, E; Cetkovsky, P; Jindra, P; Szotkowski, T; Zak, P; Mayer, J; Racil, Z, 2019: Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. BRITISH JOURNAL OF HAEMATOLOGY 186(2), p. 300 - 310, doi: 10.1111/bjh.15916
• Spunarova, M; Tom, N; Pavlova, S; Mraz, M; Brychtova, Y; Doubek, M; Panovska, A; Francova, HS; Brzobohata, A; Pospisilova, S; Mayer, J; Trbusek, M, 2019: Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience. LEUKEMIA RESEARCH 81, p. 75 - 81, doi: 10.1016/j.leukres.2019.04.015
• Cerna, K; Oppelt, J; Musilova, K; Seda, V;Pavlasova, K; Radova, L; Arigoni, M; Calogero, RA; Benes, V; Tbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S; Mraz, M, 2019: MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. LEUKEMIA
• Egle, A; Melchardt, T; Obrtlikova, P; Smolej, L; Kozak, T; Steurer, M; Andel, J; Burgstaller, S; Mikuskova, E; Gercheva, L; Nosslinger, T; Papapjik, T; Ladicka, M; Girschikofsky, M; Hrubisko, M; Jager, U; Voskova, D; Pecherstorfer, M; Kralikova, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochova, E; Palasthy, S; Stehlikova, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R, 2019: Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. CANCER MEDICINE 8(4), p. 1401 - 1405, doi: 10.1002/cam4.1980
• Herudkova, Z; Culen, M; Folta, A; Jeziskova, I; Cerna, J; Loja, T; Tom, N; Smejkal, J; Semerad, L; Dvorakova, D; Mayer, J; Racil, Z, 2019: Clonal hierarchy of main molecular lesions in acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY , doi: 10.1111/bjh.16341

2018

• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Slavikova, M; Bystry, V; Kissova, J; Gisslinger, B; Gisslinger, H; Penka, M; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2018: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. LEUKEMIA 32(2), p. 450 - 461, doi: 10.1038/leu.2017.230
• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Borsky, M; Bikos, V; Malcikova, J; Oltova, A; Kotaskova, J; Tichy, B; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2018: Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. LEUKEMIA 32(1), p. 234 - 236, doi: 10.1038/leu.2017.274
• Culen, M; Kosarova, Z; Jeziskova, I; Folta, A; Tom, N; Venglar, O; Dvorakova, D; Mayer, J; Racil, Z, 2018: Persistence of Mutations during Remission in 114 AML Patients. BLOOD 132, doi: 10.1182/blood-2018-99-110586
• Venglar, O; Culen, M; Cerna, J; Kosarova, Z; Mayer, J; Racil, Z, 2018: Long Term Culture of Primary AML and CML Cells: Effects of Growth Factor Composition on Cell Expansion and Differentiation. BLOOD 132, doi: 10.1182/blood-2018-99-112451
• Kozlova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2018: Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies. BLOOD 132, doi: 10.1182/blood-2018-99-118669
• Trizuljak, J; Kozubik, KS; Radova, L; Pesova, M; Pal, K; Reblova, K; Stehlikova, O; Smejkal, P; Zavrelova, J; Pacejka, M; Mayer, J; Pospisilova, S; Doubek, M, 2018: A novel germline mutation in GP1BA gene N-terminal domain in monoallelic Bernard-Soulier syndrome. PLATELETS 29(8), p. 827 - 833, doi: 10.1080/09537104.2018.1529300
• Kozubik, KS; Radova, L; Pesova, M; Reblova, K; Trizuljak, J; Plevova, K; Fiamoli, V; Gumulec, J; Urbankova, H; Szotkowski, T; Mayer, J; Pospisilova, S; Doubek, M, 2018: C-terminal RUNX1 mutation in familial platelet disorder with predisposition to myeloid malignancies. INTERNATIONAL JOURNAL OF HEMATOLOGY 108(6), p. 652 - 657, doi: 10.1007/s12185-018-2514-3
• Musilova, K; Devan, J; Cerna, K; Seda, V; Pavlasova, G; Sharma, S; Oppelt, J; Pytlik, R; Prochazka, V; Prouzova, Z; Trbusek, M; Zlamalikova, L; Liskova, K; Kruzova, L; Jarosova, M; Mareckova, A; Kornauth, C; Simonitsch-Klupp, I; Schiefer, A; Merkel, O; Mocikova, H; Burda, P; Polakova, K; Kren, L; Mayer, J; Zent, CS; Trneny, M; Evans, A; Janikova, A; Mraz, M, 2018: miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. BLOOD
• Culen, M; Kosarova, Z; Jeziskova, I; Folta, A; Chovancova, J; Loja, T; Tom, N; Bystry, V; Janeckova, V; Dvorakova, D; Mayer, J; Racil, Z, 2018: The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 144(7), p. 1239 - 1251, doi: 10.1007/s00432-018-2652-2

2017

• Hallek, M; Fraser, G; Cramer, P; Demirkan, F; Silva, RS; Grosicki, S; Janssens, A; Pristupa, A; Mayer, J; Dilhuydy, MS; Loscertales, J; Bartlett, N; Avigdor, A; Rule, S; Sun, S; Mahler, M; Phelps, C; Salman, M; Howes, A; Chanan-Khan, A, 2017: Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. LEUKEMIA & LYMPHOMA 58, p. 192 - 194
• Mraz, M; Cerna, K; Oppelt, J; Seda, V; Musilova, K; Pavlasova, G; Mayer, J; Pospisilova, S, 2017: MicroRNA induced by DNA damage response regulates the expression of FOXP1 and therapy response in CLL. LEUKEMIA & LYMPHOMA 58, p. 73 - 74
• Pavlasova, G; Borsky, M; Svobodova, V; Musilova, K; Cerna, K; Seda, V; Osickova, J; Brychtova, Y; Doubek, M; Pospisilova, S; Mayer, J; Mraz, M, 2017: BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO. HAEMATOLOGICA 102, p. 412 - 412
• Ledererova, A; Kozlova, V; Vakulova, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2017: B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102, p. 709 - 709
• Jeziskova, I; Semerad, L; Dvorakova, D; Janeckova, V; Culen, M; Kunetkova, T; Mayer, J; Racil, Z, 2017: Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia. LEUKEMIA & LYMPHOMA 58(3), p. 746 - 748, doi: 10.1080/10428194.2016.1213832
• Plesingerova, H; Librova, Z; Plevova, K; Libra, A; Tichy, B; Francova, HS; Vrbacky, F; Smolej, L; Mayer, J; Bryja, V; Doubek, M; Pospisilova, S, 2017: COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. LEUKEMIA & LYMPHOMA 58(1), p. 70 - 79, doi: 10.1080/10428194.2016.1180690
• Gregor, T; Rynes, J; Foldynova-Trantirkova, S; Mayer, J; Krejci, P; Trantirek, L, 2017: Systematic analysis of BCR-ABL interactome in chronic myeloid leukemia. FEBS JOURNAL 284, p. 286 - 286
• Kantorova, B; Malcikova, J; Brazdilova, K; Borsky, M; Plevova, K; Smardova, J; Radova, L; Tom, N; Trbusek, M; Diviskova, E; Francova, HS; Navrkalova, V; Doubek, M; Brychtova, Y; Mayer, J; Pospisilova, S, 2017: Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. BRITISH JOURNAL OF HAEMATOLOGY 178(6), p. 979 - 982, doi: 10.1111/bjh.14176
• Stoklasova, M; Drevojankova, B; Burdova, A; Sablaturova, I; Strnkova, A; Truhlikova, L; Lencesova, Z; Kucharova, H; Brychtova, Y; Panovska, A; Plevova, K; Oltova, A; Mayer, J; Doubek, M; Pospisilova, S; Rytikova, N; Adamova, D; Zygulova, I; Heinzova, V; Zuchnicka, J; Duras, J; Bodzasova, C; Laska, J; Urbankova, M; Jehlikova, Z; Slezak, P; Macurova, J; Janek, D; Bogoczova, E; Klodova, D; Zetkova, Z; Wrobel, M; Brejcha, M, 2017: Rare recurrent chromosomal abnormalities in CLL detected by conventional cytogenetics stimulated by CpG ODN & IL 2 and FISH. MOLECULAR CYTOGENETICS 10
• Dubovy, P; Klusakova, I; Kucera, L; Osiclova, J; Chovancova, J; Loja, T; Mayer, J; Doubek, M; Joukal, M, 2017: Local chemical sympathectomy of rat bone marrow and its effect on marrow cell composition. AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL 206, p. 19 - 27, doi: 10.1016/j.autneu.2017.06.003
• Brhelova, E; Antonova, M; Pardy, F; Kocmanova, I; Mayer, J; Racil, Z; Lengerova, M, 2017: Investigation of next-generation sequencing data of Klebsiella pneumoniae using web-based tools. JOURNAL OF MEDICAL MICROBIOLOGY 66(11), p. 1673 - 1683, doi: 10.1099/jmm.0.000624
• Vavrova, E; Kantorova, B; Vonkova, B; Kabathova, J; Skuhrova-Francova, H; Diviskova, E; Letocha, O; Kotaskova, J; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2017: Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia. LEUKEMIA RESEARCH 60, p. 145 - 150, doi: 10.1016/j.leukres.2017.08.001

2016

• Ho, AD; Schetelig, J; Bochtler, T; Schaich, M; Schafer-Eckart, K; Hanel, M; Rosler, W; Einsele, H; Kaufmann, M; Serve, H; Berde, WE; Stelljes, M; Mayer, J; Reichle, A; Baldus, CD; Schmitz, N; Kramer, M; Rollig, C; Bornhauser, M; Thiede, C; Ehninger, G, 2016: Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 22(3), p. 462 - 469, doi: 10.1016/j.bbmt.2015.10.023
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Kissova, J; Gisslinger, B; Gisslinger, H; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2016: Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128(22)
• Smida, M; Kozlova, V; Vakulova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S, 2016: Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies. BLOOD 128(22)
• Ricna, D; Lengerova, M; Palackova, M; Hadrabova, M; Kocmanova, I; Weinbergerova, B; Pavlovsky, Z; Volfova, P; Bouchnerova, J; Mayer, J; Racil, Z, 2016: Disseminated fusariosis by Fusarium proliferatum in a patient with aplastic anaemia receiving primary posaconazole prophylaxis - case report and review of the literature. MYCOSES 59(1), p. 48 - 55, doi: 10.1111/myc.12421
• Brhelova, E; Kocmanova, I; Racil, Z; Hanslianova, M; Antonova, M; Mayer, J; Lengerova, M, 2016: Validation of Minim typing for fast and accurate discrimination of extended-spectrum, beta-lactamase-producing Klebsiella pneumoniae isolates in tertiary care hospital. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE 86(1), p. 44 - 49, doi: 10.1016/j.diagmicrobio.2016.03.010
• Greil, R; Obrtlikova, P; Smolej, L; Kozak, T; Steurer, M; Andel, J; Burgstaller, S; Mikuskova, E; Gercheva, L; Nosslinger, T; Papajik, T; Ladicka, M; Girschikofsky, M; Hrubisko, M; Jager, U; Fridrik, M; Pecherstorfer, M; Kralikova, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochova, E; Palasthy, S; Stehlikova, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A, 2016: Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. LANCET HAEMATOLOGY 3(7), p. E317 - E329, doi: 10.1016/S2352-3026(16)30045-X
• Bezdicek, M; Lengerova, M; Ricna, D; Weinbergerova, B; Kocmanova, I; Volfova, P; Drgona, L; Poczova, M; Mayer, J; Racil, Z, 2016: Rapid detection of fungal pathogens in bronchoalveolar lavage samples using panfungal PCR combined with high resolution melting analysis. MEDICAL MYCOLOGY 54(7), p. 714 - 724, doi: 10.1093/mmy/myw032
• Culen, M; Borsky, M; Nemethova, V; Razga, F; Smejkal, J; Jurcek, T; Dvorakova, D; Zackova, D; Weinbergerova, B; Semerad, L; Sadovnik, I; Eisenwort, G; Herrmann, H; Valent, P; Mayer, J; Racil, Z, 2016: Quantitative assessment of the CD26+leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects. ONCOTARGET 7(22), p. 33016 - 33024, doi: 10.18632/oncotarget.9108
• Cortes, JE; Saglio, G; Kantarjian, HM; Baccarani, M; Mayer, J; Boque, C; Shah, NP; Chuah, C; Casanova, L; Bradley-Garelik, B; Manos, G; Hochhaus, A, 2016: Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. JOURNAL OF CLINICAL ONCOLOGY 34(20), p. 2333 - U54, doi: 10.1200/JCO.2015.64.8899

2015

• Pavlasova, G; Seda, V; Borsky, M; Cerna, K; Osickova, J; Mayer, J; Pospisilova, S; Davids, MS; Brown, JR; Mraz, M, 2015: Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. BLOOD 126(23)
• Kantorova, B; Malcikova, J; Brazdilova, K; Borsky, M; Plevova, K; Smardova, J; Trbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD 126(23)
• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Chmelikova, M; Borsky, M; Burckova, K; Kantorova, B; Tichy, B; Skabrahova, H; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2015: Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry. BLOOD 126(23)
• Pavlasova, G; Borsky, M; Seda, V; Cerna, K; Osickova, J; Mayer, J; Pospisilova, S; Davids, M; Brown, J; Mraz, M, 2015: Microenvironmental interactions up-regulate CD20 expression in CLL B cells, but confer resistance to rituximab. LEUKEMIA & LYMPHOMA 56, p. 76 - 77
• Verner, J; Trbusek, M; Chovancova, J; Jaskova, Z; Moulis, M; Folber, F; Halouzka, R; Mayer, J; Pospisilova, S; Doubek, M, 2015: NOD/SCID IL2R gamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines. LEUKEMIA & LYMPHOMA 56(11), p. 3198 - 3206, doi: 10.3109/10428194.2015.1034701
• Jeziskova, I; Musilova, M; Culen, M; Foltankova, V; Dvorakova, D; Mayer, J; Racil, Z, 2015: Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. INTERNATIONAL JOURNAL OF HEMATOLOGY 102(5), p. 553 - 557, doi: 10.1007/s12185-015-1856-3
• Jeziskova, I; Musilova, M; Culen, M; Foltankova, V; Dvorakova, D; Mayer, J; Racil, Z, 2015: DNMT3A Gene: Distribution of the Mutations and their Stability during Treatment in Patients with AML. ANNALS OF HEMATOLOGY 94, p. S78 - S78
• Kotaskova, J; Malcikova, J; Diviskova, E; Pavlova, S; Mejstrikova, S; Vranova, V; Plevova, K; Plesingerova, H; Doubek, M; Mayer, J; Pospisilova, S, 2015: 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100, p. 417 - 418
• Tom, N; Malcikova, J; Radova, L; Kantorova, B; Pardy, F; Pavlova, S; Pal, K; Mraz, M; Tichy, B; Doubek, M; Brychtova, Y; Plevova, K; Mayer, J; Trbusek, M; Pospisilova, S, 2015: MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100, p. 224 - 225
• Jaskova, Z; Malcikova, J; Smardova, J; Brychtova, Y; Mayer, J; Trbusek, M, 2015: ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET. HAEMATOLOGICA 100, p. 414 - 414
• Zemanova, J; Paruch, K; Krejci, L; Soucek, K; Hylse, O; Boudny, M; Borsky, M; Osickova, J; Khirsariya, P; Sebejova, L; Navrkalova, V; Malcikova, J; Diviskova, E; Brychtova, Y; Mayer, J; Trbusek, M, 2015: CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1. HAEMATOLOGICA 100, p. 417 - 417
• Malcikova, J; Stano-Kozubik, K; Tichy, B; Kantorova, B; Pavlova, S; Tom, N; Radova, L; Smardova, J; Pardy, F; Doubek, M; Brychtova, Y; Mraz, M; Plevova, K; Diviskova, E; Oltova, A; Mayer, J; Pospisilova, S; Trbusek, M, 2015: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29(4), p. 877 - 885, doi: 10.1038/leu.2014.297
• Chovancova, J; Bernard, T; Stehlikova, O; Salek, D; Janikova, A; Mayer, J; Doubek, M, 2015: Detection of Minimal Residual Disease in Mantle Cell Lymphoma-Establishment of Novel Eight-Color Flow Cytometry Approach. CYTOMETRY PART B-CLINICAL CYTOMETRY 88(2), p. 92 - 100, doi: 10.1002/cyto.b.21210
• Trizuljak, J; Srovnal, J; Plevova, K; Brychtova, Y; Semerad, L; Bakesova, D; Letalova, E; Benedikova, A; Mayer, J; Hajduch, M; Pospisilova, S; Doubek, M, 2015: Analysis of Prognostic Significance of Merkel Cell Polyomavirus in Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 15(7), p. 439 - 442, doi: 10.1016/j.clml.2015.02.003
• Cervinek, L; Mayer, J; Doubek, M, 2015: Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. INTERNATIONAL JOURNAL OF HEMATOLOGY 102(1), p. 7 - 11, doi: 10.1007/s12185-015-1793-1
• Kantorova, B; Malcikova, J; Smardova, J; Pavlova, S; Trbusek, M; Tom, N; Plevova, K; Tichy, B; Truong, S; Diviskova, E; Kotaskova, J; Oltova, A; Patten, N; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. TUMOR BIOLOGY 36(5), p. 3371 - 3380, doi: 10.1007/s13277-014-2971-0

2014

• Jabbour, E; Kantarjian, HM; Saglio, G; Steegmann, JL; Shah, NP; Boque, C; Chuah, C; Pavlovsky, C; Mayer, J; Cortes, J; Baccarani, M; Kim, DW; Bradley-Garelik, MB; Mohamed, H; Wildgust, M; Hochhaus, A, 2014: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). BLOOD 123(4), p. 494 - 500, doi: 10.1182/blood-2013-06-511592
• Brejcha, M; Stoklasova, M; Brychtova, Y; Panovska, A; Stepanovska, K; Vankova, G; Plevova, K; Oltova, A; Horka, K; Pospisilova, S; Mayer, J; Doubek, M, 2014: Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: A prospective analysis. LEUKEMIA RESEARCH 38(2), p. 170 - 175, doi: 10.1016/j.leukres.2013.10.019
• Fiegl, M; Stauder, R; Steurer, M; Mian, M; Hopfinger, G; Brychtova, Y; Skrabs, C; Zabernigg, A; Schmid, F; Haslbaur, F; Winder, G; Walder, A; Lang, A; Voskova, D; Greil, R; Mayer, J; Gastl, G, 2014: Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. ANNALS OF HEMATOLOGY 93(2), p. 267 - 277, doi: 10.1007/s00277-013-1966-z
• Plevova, K; Francova, HS; Burckova, K; Brychtova, Y; Doubek, M; Pavlova, S; Malcikova, J; Mayer, J; Tichy, B; Pospisilova, S, 2014: Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. HAEMATOLOGICA 99(2), p. 329 - 338, doi: 10.3324/haematol.2013.087593
• Mayer, J; Arthur, C; Delaunay, J; Mazur, G; Thomas, XG; Wierzbowska, A; Ravandi, F; Berrak, E; Jones, M; Li, YH; Kantarjian, HM, 2014: Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor-or intermediate-risk cytogenetics. BMC CANCER 14, doi: 10.1186/1471-2407-14-69
• Stehlikova, O; Chovancova, J; Tichy, B; Krejci, M; Brychtova, Y; Panovska, A; Skuhrova, HF; Burckova, K; Borsky, M; Loja, T; Mayer, J; Pospisilova, S; Doubek, M, 2014: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 36(2), p. 165 - 171, doi: 10.1111/ijlh.12149
• Kminkova, J; Mraz, M; Zaprazna, K; Navrkalova, V; Tichy, B; Plevova, K; Malcikova, J; Cerna, K; Rausch, T; Benes, V; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2014: Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia. CARCINOGENESIS 35(5), p. 992 - 1002, doi: 10.1093/carcin/bgt396
• Racil, Z; Razga, F; Klamova, H; Voglova, J; Belohlavkova, P; Malaskova, L; Potesil, D; Muzik, J; Zackova, D; Polakova, KM; Zdrahal, Z; Malakova, J; Suttnar, J; Dyr, J; Mayer, J, 2014: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia. HEMATOLOGICAL ONCOLOGY 32(2), p. 87 - 93, doi: 10.1002/hon.2091
• Doubek, M; Srovnal, J; Plevova, K; Trizuljak, J; Brychtova, Y; Semerad, L; Letalova, E; Benedikova, A; Mayer, J; Hajduch, M; Pospisilova, S, 2014: ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 99, p. 325 - 325
• Valent, P; Sadovnik, I; Racil, Z; Herrmann, H; Blatt, K; Cerny-Reiterer, S; Eisenwort, G; Lion, T; Holyoake, T; Mayer, J, 2014: DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 44(12), p. 1239 - 1245, doi: 10.1111/eci.12368
• Verner, J; Trbusek, M; Chovancova, J; Skabrahova, H; Jaskova, Z; Moulis, M; Folber, F; Halouzka, R; Mayer, J; Pospisilova, S; Doubek, M, 2014: NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53-AND/OR ATM-DEFICIENT CELL LINES. HAEMATOLOGICA 99, p. 312 - 313
• Navrkalova, V; Mareckova, A; Janikova, A; Doubek, M; Mayer, J; Pospisilova, S; Trbusek, M, 2014: INCORPORATION OF NEXT-GENERATION SEQUENCING INTO ATM GENE ANALYSIS IN PATIENTS WITH CLL AND MCL. HAEMATOLOGICA 99, p. 312 - 312
• Lindoerfer, D; Hoffmann, VS; Rosti, G; Castagnetti, F; Saussele, S; Guilhot, J; Simonsson, B; Steegmann, JL; Mayer, J; Indrak, K; Turkina, AG; Zaritskey, A; Labar, B; Zupan, IP; Thielen, N; Clark, RE; Thaler, J; Melanthiou, F; Everaus, H; Porkka, K; Bogda, 2014: THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES. HAEMATOLOGICA 99, p. 238 - 239
• Skrivanova, K; Brancikova, D; Bendova, M; Sverak, T; Elfmarkova, N; Anderkova, L; Peterkova, H; Adolfova, L; Dusek, L; Jarkovsky, J; Gregor, J; Nedved, J; Minar, L; Ventruba, P; Mayer, J; Temoshok, L, 2014: Evaluating Disease and Patient Characteristics Which Predict (Retrospectively) Changes in Quality of Life After Breast Cancer Diagnosis and Treatment. PSYCHO-ONCOLOGY 23, p. 396 - 397
• Hoffmann, V; Lindoerfer, D; Thaler, J; Labar, B; Melanthiou, F; Mayer, J; Everaus, H; Porkka, K; Guillhot, J; Schubert-Fritschle, G; Castagnetti, F; Lejniece, S; Griskevicius, L; Thielen, N; Hellmann, A; Turkina, A; Zaritskey, A; Bogdanovic, AD; Indrak, K, 2014: THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE. HAEMATOLOGICA 99, p. 72 - 72
• Cerna, K; Oppelt, J; Radova, L; Pardy, F; Tom, N; Musilova, K; Malcikova, J; Plevova, K; Tichy, B; Brychtova, Y; Doubek, M; Trbusek, M; Koca, J; Calogero, R; Mayer, J; Pospisilova, S; Mraz, M, 2014: BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNAS INDUCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS DURING ADMINISTRATION OF THERAPY IN VIVO AND IN VITRO. HAEMATOLOGICA 99, p. 41 - 42
• Robesova, B; Bajerova, M; Liskova, K; Skrickova, J; Tomiskova, M; Pospisilova, S; Mayer, J; Dvorakova, D, 2014: TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC. LUNG CANCER 85(1), p. 25 - 30, doi: 10.1016/j.lungcan.2014.04.002
• Lengerova, M; Racil, Z; Hrncirova, K; Kocmanova, I; Volfova, P; Ricna, D; Bejdak, P; Moulis, M; Pavlovsky, Z; Weinbergerova, B; Toskova, M; Mayer, J, 2014: Rapid Detection and Identification of Mucormycetes in Bronchoalveolar Lavage Samples from Immunocompromised Patients with Pulmonary Infiltrates by Use of High-Resolution Melt Analysis. JOURNAL OF CLINICAL MICROBIOLOGY 52(8), p. 2824 - 2828, doi: 10.1128/JCM.00637-14
• Janikova, A; Mareckova, A; Baumeisterova, A; Krejci, M; Supikova, J; Salek, D; Horky, O; Tichy, B; Hanke, I; Pospisilova, S; Moulis, M; Mayer, J, 2014: Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma. LEUKEMIA & LYMPHOMA 55(8), p. 1935 - 1938, doi: 10.3109/10428194.2013.858150
• Jurcek, T; Razga, F; Mazancova, P; Musilova, M; Dvorakova, D; Borsky, M; Zackova, D; Dobesova, B; Semerad, L; Mayer, J; Racil, Z, 2014: Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia. LEUKEMIA & LYMPHOMA 55(8), p. 1915 - 1917, doi: 10.3109/10428194.2013.842988
• Volfova, P; Lengerova, M; Lochmanova, J; Dvorakova, D; Ricna, D; Palackova, M; Weinbergerova, B; Mayer, J; Racil, Z, 2014: Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR. JOURNAL OF CLINICAL VIROLOGY 61(2), p. 270 - 274, doi: 10.1016/j.jcv.2014.07.008
• Musilova, M; Razga, F; Jurcek, T; Jeziskova, I; Borsky, M; Nemethova, V; Zackova, D; Culen, M; Dvorakova, D; Mayer, J; Racil, Z, 2014: BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing. AMERICAN JOURNAL OF HEMATOLOGY 89(10), p. 1016 - 1017, doi: 10.1002/ajh.23794
• Sebejova, L; Borsky, M; Jaskova, Z; Potesil, D; Navrkalova, V; Malcikova, J; Sramek, M; Doubek, M; Loja, T; Pospisilova, S; Mayer, J; Trbusek, M, 2014: Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. EXPERIMENTAL HEMATOLOGY 42(10), p. 867 - 874, doi: 10.1016/j.exphem.2014.06.003

2013

• Szturz, P; Adam, Z; Vasku, V; Feit, J; Krejci, M; Pour, L; Hajek, R; Mayer, J, 2013: Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. LEUKEMIA & LYMPHOMA 54(6), p. 1324 - 1326, doi: 10.3109/10428194.2012.738816
• Dvorakova, D; Racil, Z; Borsky, M; Robesova, B; Jeziskova, I; Razga, F; Lengerova, M; Mayer, J, 2013: Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations. LEUKEMIA & LYMPHOMA 54(5), p. 1056 - 1060, doi: 10.3109/10428194.2012.734618
• Adam, Z; Szturz, P; Vanicek, J; Moulis, M; Pour, L; Krejci, M; Hajek, R; Mayer, J, 2013: Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. ACTA ONCOLOGICA 52(5), p. 994 - 1001, doi: 10.3109/0284186X.2012.716164
• SZTURZ, P.;Z. ADAM;Z. REHAK;R. KOUKALOVA;A. SPRLAKOVA-PUKOVA;J. MICHALKA;L. SMARDOVA;P. VOLFOVA;M. LENGEROVA;J. MAYER., 2013: Castlemanova choroba: Retrospektivni studie lecebnych vysledku u 10 pacientu z jednoho centra. KLINICKA ONKOLOGIE 26, p. 124 - 134
• Panovska, A; Smolej, L; Lysak, D; Brychtova, Y; Simkovic, M; Motyckova, M; Vodarek, P; Lindtnerova, M; Trbusek, M; Malcikova, J; Pospisilova, S; Mayer, J; Doubek, M, 2013: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. EUROPEAN JOURNAL OF HAEMATOLOGY 90(6), p. 479 - 485, doi: 10.1111/ejh.12106
• ADAM, Z.;J. KREJCI;M. KREJCI;P. NEMEC;L. SPINAROVA;V. ZAMPACHOVA;Z. CERMAKOVA;T. PIKA;L. POUR;Z. KORISTEK;M. TOMISKA;P. SZTURZ;Z. KRAL;J. MAYER., 2013: Transplantace srdce a nasledna lecba AL-amyloidozy. VNITRNI LEKARSTVI 59, p. 136 - 147
• Simara, P; Stejskal, S; Koutna, I; Potesil, D; Tesarova, L; Potesilova, M; Zdrahal, Z; Mayer, J, 2013: Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. AMERICAN JOURNAL OF HEMATOLOGY 88(5), p. 385 - 393, doi: 10.1002/ajh.23419
• Toskova, M; Palousova, D; Kocmanova, I; Pavlovsky, Z; Timilsina, S; Lengerova, M; Mayer, J; Racil, Z, 2013: Invasive mould disease involving the gastrointestinal tract caused by Neosartorya pseudofischeri in a haematological patient. MYCOSES 56(3), p. 385 - 388, doi: 10.1111/myc.12038
• Racil, Z; Weinbergerova, B; Kocmanova, I; Muzik, J; Kouba, M; Drgona, L; Masarova, L; Gumang, T; Tothova, E; Forsterova, K; Haber, J; Ziakova, B; Bojtarova, E; Vydra, J; Mudry, P; Foralova, R; Sejnova, D; Mallatova, N; Kandrnal, V; Cetkovsky, P; Mayer, J, 2013: Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005-2009. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 17(2), p. E101 - E109, doi: 10.1016/j.ijid.2012.09.004
• Pfeiffer, T; Schleuning, M; Mayer, J; Haude, KH; Tischer, J; Buchholz, S; Bunjes, D; Bug, G; Holler, E; Meyer, RG; Greinix, H; Scheid, C; Christopeit, M; Schnittger, S; Braess, J; Schlimok, G; Spiekermann, K; Ganser, A; Kolb, HJ; Schmid, C, 2013: Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. HAEMATOLOGICA 98(4), p. 518 - 525, doi: 10.3324/haematol.2012.070235
• Schaich, M; Parmentier, S; Kramer, M; Illmer, T; Stolzel, F; Rollig, C; Thiede, C; Hanel, M; Schafer-Eckart, K; Aulitzky, W; Einsele, H; Ho, AD; Serve, H; Berdel, WE; Mayer, J; Schmitz, N; Krause, SW; Neubauer, A; Baldus, CD; Schetelig, J; Bornhaeuser, M;, 2013: High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. JOURNAL OF CLINICAL ONCOLOGY 31(17), p. 2094 - +, doi: 10.1200/JCO.2012.46.4743
• Coiffier, B; Li, WM; Henitz, ED; Karkera, JD; Favis, R; Gaffney, D; Shapiro, A; Theocharous, P; Elsayed, YA; van de Velde, H; Schaffer, ME; Osmanov, EA; Hong, XN; Scheliga, A; Mayer, J; Offner, F; Rule, S; Teixeira, A; Romejko-Jarosinska, J; de Vos, S; Cr, 2013: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab. CLINICAL CANCER RESEARCH 19(9), p. 2551 - 2561, doi: 10.1158/1078-0432.CCR-12-3069
• Racil, Z; Toskova, M; Kocmanova, I; Buresova, L; Kouba, M; Drgona, L; Masarova, L; Guman, T; Tothova, E; Gabzdilova, J; Forsterova, K; Haber, J; Ziakova, B; Bojtarova, E; Rolencova, M; Timilsina, S; Cetkovsky, P; Mayer, J, 2013: Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. LEUKEMIA & LYMPHOMA 54(5), p. 1042 - 1047, doi: 10.3109/10428194.2012.729057
• SZTURZ, P.;J. KYCLOVA;M. MOULIS;M. NAVRATIL;Z. ADAM;J. VANICEK;J. MAYER., 2013: Extensive AL Amyloidosis Presenting with Recurrent Liver Hemorrhage and Hemoperitoneum: Case Report and Literature Review. KLINICKA ONKOLOGIE 26, p. 49 - 52
• Krejci, M; Doubek, M; Dusek, J; Brychtova, Y; Racil, Z; Navratil, M; Tomiska, M; Horky, O; Pospisilova, S; Mayer, J, 2013: Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. ANNALS OF HEMATOLOGY 92(10), p. 1397 - 1403, doi: 10.1007/s00277-013-1790-5
• Pavlik, T; Janousova, E; Mayer, J; Indrak, K; Jarosova, M; Klamova, H; Zackova, D; Voglova, J; Faber, E; Karas, M; Polakova, KM; Racil, Z; Demeckova, E; Demitrovicova, L; Tothova, E; Chudej, J; Markuljak, I; Cmunt, E; Kozak, T; Muzik, J; Dusek, L, 2013: Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. AMERICAN JOURNAL OF HEMATOLOGY 88(9), p. 790 - 797, doi: 10.1002/ajh.23508
• Racil, Z; Razga, F; Drapalova, J; Buresova, L; Zackova, D; Palackova, M; Semerad, L; Malaskova, L; Haluzik, M; Mayer, J, 2013: Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. HAEMATOLOGICA 98(10), doi: 10.3324/haematol.2013.086355
• Baccarani, M; Deininger, MW; Rosti, G; Hochhaus, A; Soverini, S; Apperley, JF; Cervantes, F; Clark, RE; Cortes, JE; Guilhot, F; Hjorth-Hansen, H; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Muller, MC; , 2013: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. BLOOD 122(6), p. 872 - 884, doi: 10.1182/blood-2013-05-501569
• Zackova, D; Klamova, H; Muzik, J; Cmunt, E; Racil, Z; Polakova, KM; Dvorakova, D; Jurcek, T; Razga, F; Cetkovsky, P; Dusek, L; Mayer, J, 2013: Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. LEUKEMIA & LYMPHOMA 54(10), p. 2310 - 2313, doi: 10.3109/10428194.2013.772173
• Hoffmann, VS; Baccarani, M; Lindoerfer, D; Castagnetti, F; Turkina, A; Zaritsky, A; Hellmann, A; Prejzner, W; Steegmann, JL; Mayer, J; Indrak, K; Colita, A; Rosti, G; Pfirrmann, M, 2013: The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. LEUKEMIA 27(10), p. 2016 - 2022, doi: 10.1038/leu.2013.171
• Malcikova, J; Razga, F; Jurcek, T; Dvorakova, D; Zackova, D; Toskova, M; Sebejova, L; Smardova, J; Oltova, A; Vankova, G; Jurackova, L; Trbusek, M; Pospisilova, S; Mayer, J; Racil, Z, 2013: The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. LEUKEMIA & LYMPHOMA 54(9), p. 2083 - 2087, doi: 10.3109/10428194.2012.762649
• Racil, Z; Kocmanova, I; Toskova, M; Winterova, J; Lengerova, M; Timilsina, S; Mayer, J, 2013: Reactivity of the 1,3-beta-D-glucan assay during bacteraemia: limited evidence from a prospective study. MYCOSES 56(2), p. 101 - 104, doi: 10.1111/j.1439-0507.2012.02210.x
• Jeziskova, I; Razga, F; Toskova, M; Dvorakova, D; Timilsina, S; Mayer, J; Racil, Z, 2013: Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. LEUKEMIA & LYMPHOMA 54(4), p. 867 - 870, doi: 10.3109/10428194.2012.727414
• Fink, AM; Bottcher, S; Ritgen, M; Fischer, K; Pflug, N; Eichhorst, B; Wendtner, CM; Winkler, D; Buhler, A; Zenz, T; Staib, P; Mayer, J; Hensel, M; Hopfinger, G; Wenger, M; Fingerle-Rowson, G; Dohner, H; Kneba, M; Stilgenbauer, S; Busch, R; Hallek, M, 2013: Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. LEUKEMIA 27(9), p. 1949 - 1952, doi: 10.1038/leu.2013.190

2012

• Szturz, P; Adam, Z; Chovancova, J; Stehlikova, O; Klabusay, M; Feit, J; Kren, L; Fojtik, Z; Krejci, M; Pour, L; Hajek, R; Mayer, J, 2012: Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease. LEUKEMIA & LYMPHOMA 53(4), p. 743 - 745, doi: 10.3109/10428194.2011.627482
• MRAZ, M.;M. TRBUSEK;D. DOLEZALOVA;J. MALCIKOVA;J. SUPIKOVA;K. STANO KOZUBIK;B. KANTOROVA;J. MAYER;S. POSPISILOVA., 2012: Identifikace patogeneticky vyznamnych mutaci u chronicke lymfocytarni leukemie pomoci ´sekvenovani nove generace´. TRANSFUZE A HEMATOLOGIE DNES 18, p. 72 - 75
• Verner, J; Kabathova, J; Tomancova, A; Pavlova, S; Tichy, B; Mraz, M; Brychtova, Y; Krejci, M; Zdrahal, Z; Trbusek, M; Volejnikova, J; Sedlacek, P; Doubek, M; Mayer, J; Pospisilova, S, 2012: Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation. EXPERIMENTAL HEMATOLOGY 40(11), p. 899 - 905, doi: 10.1016/j.exphem.2012.06.011
• Mraz, M; Dolezalova, D; Plevova, K; Kozubik, KS; Mayerova, V; Cerna, K; Musilova, K; Tichy, B; Pavlova, S; Borsky, M; Verner, J; Doubek, M; Brychtova, Y; Trbusek, M; Hampl, A; Mayer, J; Pospisilova, S, 2012: MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. BLOOD 119(9), p. 2110 - 2113, doi: 10.1182/blood-2011-11-394874
• ADAM, Z.;P. SZTURZ;P. BUCKOVA;I. CERVINKOVA;R. KOUKALOVA;Z. REHAK;M. KREJCI;L. POUR;L. ZAHRADOVA;R. HAJEK;Z. KRAL;J. MAYER., 2012: Blokada receptoru pro interleukin-1 preparatem anakinra vedla u pacienta s Erdheimovou-Chesterovou nemoci k vymizeni patologicke unavy, k poklesu markeru zanetu a ustupu fibrozy v retroperitoneu – popis pripadu a prehled literarnich udaju. VNITRNI LEKARSTVI 58, p. 313 - 318
• Razga, F; Jurcek, T; Jeziskova, I; Zackova, D; Dvorakova, D; Borsky, M; Mayer, J; Racil, Z, 2012: Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing Detection of the T315I Mutation in Bone Marrow CD34+Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood. MOLECULAR DIAGNOSIS & THERAPY 16(3), p. 163 - 166
• Doubek, M; Trbusek, M; Malcikova, J; Brychtova, Y; Smardova, J; Lochmanova, J; Panovska, A; Francova, HS; Mraz, M; Tichy, B; Sebejova, L; Navrkalova, V; Plevova, K; Kuglik, P; Mayer, J; Pospisilova, S, 2012: Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 53(9), p. 1817 - 1819, doi: 10.3109/10428194.2012.658794
• BEJDAK, P.;M. LENGEROVA;D. PALOUSOVA;P. VOLFOVA;I. KOCMANOVA;J. MAYER;Z. RACIL., 2012: Detekce a identifikace puvodcu mykotickych infekci zpusobenych vlaknitymi houbami pomoci metod molekularni genetiky. KLINICKA MIKROBIOLOGIE A INFEKCNI LEKARSTVI 18, p. 109 - 114
• ADAM, Z.;L. POUR;M. MATYSKOVA;M. KREJCI;M. TOMISKA;P. SZTURZ;Z. REHAK;R. KOUKALOVA;L. KRIKAVOVA;T. NEBESKY;C. NEUMAN;M. NAVRATIL;R. HAJEK;Z. KRAL;J. MAYER., 2012: Vyvoj koagulacnich markeru chronicke diseminovane intravaskularni koagulace (DIK) u pacienta s mnohocetnou angiomatozou v prubehu lecby antiangiogennimi leky: interferonem alfa, thalidomidem a lenalidomidem. VNITRNI LEKARSTVI 58, p. 145 - 153
• ADAM, Z.;L. POUR;M. KREJCI;L. ZAHRADOVA;P. SZTURZ;R. KOUKALOVA;Z. REHAK;T. NEBESKY;R. HAJEK;Z. KRAL;J. MAYER., 2012: Ucinnost lenalidomidu u vzacnych krevnich chorob: u histiocytozy z Langerhansovych bunek, multicentricke Castlemanovy choroby, POEMS syndromu, Erdheimovy-Chesterovy choroby a angiomatozy. Popis pripadu a prehled literatury. VNITRNI LEKARSTVI 58, p. 856 - 866
• Racil, Z; Toskova, M; Dvorakova, D; Jeziskova, I; Razga, F; Buresova, L; Timilsina, S; Mayer, J, 2012: Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. AMERICAN JOURNAL OF HEMATOLOGY 87(2), p. 211 - 213, doi: 10.1002/ajh.22213
• ADAM, Z.;G. CHLUPOVA;A. NEUMANN;B. JAKUBCOVA;J. SIMONIDES;Z. ADAMOVA;J. KONIG;P. KRUPA;P. SZTURZ;L. POUR;M. KREJCI;R. HAJEK;Z. KRAL;J. MAYER., 2012: Teleangiectasia hereditaria haemorrhagica – syndrom Osler-Weber-Rendu. Popis pripadu a zkusenosti s lecbou. VNITRNI LEKARSTVI 58, p. 477 - 489
• MALASKOVA, L.;J. WINTEROVA;M. DASTYCH;Z. RACIL;I. KOCMANOVA;M. TOSKOVA;J. MAYER., 2012: Soubezne stanoveni vorikonazolu a posakonazolu v plazme metodou HPLC. CHEMICKE LISTY 106, p. 677 - 680
• ADAM, Z.;M. MATYSKOVA;M. TOMISKA;Z. REHAK;R. KOUKALOVA;L. KRIKAVOVA;L. POUR;M. KREJCI;P. SZTURZ;L. ZAHRADOVA;M. MECHL;M. MOULIS;J. VANICEK;C. NEUMAN;M. NAVRATIL;K. VESELY;R. HAJEK;J. MAYER., 2012: Sestilete sledovani pacienta s mnohocetnou angiomatozou postihujici skelet, brisni i hrudni dutinu a stenu travici trubice. KLINICKA ONKOLOGIE 25, p. 47 - 62
• KOLAR, M.;V. ADAMKOVA;O. NYC;E. BOJTAROVA;P. CETKOVSKY;L. DRGONA;T. GUMAN;J. HABER;J. HORAKOVA;M. KARAS;I. KOCMANOVA;M. KOUBA;A. LIGOVA;N. MALLATOVA;P. MUDRY;J. NOVAK;P. SEDLACEK;D. SEJNOVA;E. TOTHOVA;P. ZAK;B. ZIAKOVA;J. MAYER;Z. RACIL., 2012: Screening methicilin-rezistentnich kmenu Staphylococcus aureus, vankomycin-rezistentnich enterokoku a enterobakterii s produkci sirokospektrych beta-laktamaz na hematoonkologickych oddelenich. Doporuceni odborniku s podporou CELL. POSTGRADUALNI MEDICINA 14, p. 34 - 36
• Razga, F; Jurcek, T; Zackova, D; Dvorakova, D; Toskova, M; Jeziskova, I; Mayer, J; Racil, Z, 2012: Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations. MOLECULAR DIAGNOSIS & THERAPY 16(4), p. 251 - 259
• JANIKOVA, A.;J. RADVANSKY;R. VYSOKY;L. BATALIK;J. SUPITOVA;D. ZACKOVA;Z. RACIL;J. MAYER., 2012: Vyznam fyzicke aktivity u pacientu s hematoonkologickymi malignitami. TRANSFUZE A HEMATOLOGIE DNES 18, p. 31 - 38
• Janikova, A; Mareckova, A; Dvorakova, D; Bortlicek, Z; Tichy, B; Navratil, M; Kral, Z; Pospisilova, S; Mayer, J, 2012: A real-time (PCR) for a real life ...? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice. EXPERIMENTAL HEMATOLOGY 40(7), p. 528 - 539, doi: 10.1016/j.exphem.2012.02.005
• Kantarjian, HM; Thomas, XG; Dmoszynska, A; Wierzbowska, A; Mazur, G; Mayer, J; Gau, JP; Chou, WC; Buckstein, R; Cermak, J; Kuo, CY; Oriol, A; Ravandi, F; Faderl, S; Delaunay, J; Lysak, D; Minden, M; Arthur, C, 2012: Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY 30(21), p. 2670 - 2677, doi: 10.1200/JCO.2011.38.9429
• Lochmanova, G; Jedlickova, L; Potesil, D; Tomancova, A; Verner, J; Pospisilova, S; Doubek, M; Mayer, J; Zdrahal, Z, 2012: Potential biomarkers for early detection of acute graft-versus-host disease. PROTEOMICS CLINICAL APPLICATIONS 6(42223), p. 351 - 363, doi: 10.1002/prca.201100104
• RACIL, Z.;I. KOCMANOVA;M. TOSKOVA;J. WINTEROVA;M. LENGEROVA;S. TIMILSINA;J. MAYER., 2012: Reactivity of the 1,3-b-D-glucan assay during bacteraemia: limited evidence from a prospective study. MYCOSES
• Finke, J; Schmoor, C; Bethge, WA; Ottinger, HD; Stelljes, M; Zander, AR; Volin, L; Heim, DA; Schwerdtfeger, R; Kolbe, K; Mayer, J; Maertens, JA; Linkesch, W; Holler, E; Koza, V; Bornhauser, M; Einsele, H; Bertz, H; Grishina, O; Socie, G, 2012: Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 18(11), p. 1716 - 1726, doi: 10.1016/j.bbmt.2012.06.001
• ADAM, Z.;M. ELLEDER;M. MOULIS;M. TICHY;I. CERVINKOVA;Z. REHAK;R. KOUKALOVA;Z. FOJTIK;I. HANKE;L. POUR;M. KREJCI;L. ZAHRADOVA;P. SZTURZ;R. HAJEK;Z. KRAL;J. MAYER., 2012: Prinos PET-CT vysetreni pro rozhodovani o lecbe lokalizovane nodularni formy plicni AL-amyloidozy. VNITRNI LEKARSTVI 58, p. 241 - 252
• NYC, O.;M. KOLAR;V. ADAMKOVA;E. BOJTAROVA;P. CETKOVSKY;L. DRGONA;T. GUMAN;J. HABER;J. HORAKOVA;M. KARAS;I. KOCMANOVA;M. KOUBA;A. LIGOVA;N. MALLATOVA;P. MUDRY;J. NOVAK;P. SEDLACEK;D. SEJNOVA;E. TOTHOVA;P. ZAK;B. ZIAKOVA;J. MAYER;Z. RACIL., 2012: Laboratorni zachyt toxigennich kmenu Cd (Clostridium difficile), epidemiologicka opatreni a antibioticka lecba CDI (Clostridium difficile Infection) na hematoonkologickych oddelenich. Doporuceni odborniku s podporou CELL.. POSTGRADUALNI MEDICINA 14, p. 37 - 38
• ADAM, Z.;P. SZTURZ;M. KREJCI;L. POUR;L. ZAHRADOVA;Z. REHAK;R. KOUKALOVA;Z. KRAL;V. VASKU;J. MAYER., 2012: Kozni a mimokozni projevy histiocytozy z Langerhansovych bunek v obrazech. CESKA DERMATOVENEROLOGIE 2, p. 22 - 27
• ADAM, Z.;P. SZTURZ;L. POUR;M. KREJCI;L. ZAHRADOVA;M. TOMISKA;Z. KRAL;R. KOUKALOVA;Z. REHAK;J. MAYER., 2012: Kladribin je velmi ucinnym lekem pro lecbu histiocytozy z Langerhansovych bunek a vzacnych histiocytarnich nemoci ze skupiny juvenilniho xantogranulomu. VNITRNI LEKARSTVI 58, p. 455 - 465
• Krejci, M; Kamelander, J; Pospisil, Z; Mayer, J, 2012: Kinetics of bilirubin and liver enzymes is useful for predicting of liver graft-versus-host disease. NEOPLASMA 59(3), p. 264 - 268, doi: 10.4149/neo_2012_034
• PALOUSOVA, D.;M. LENGEROVA;P. VOLFOVA;P. BEJDAK;I. KOCMANOVA;J. MAYER;Z. RACIL., 2012: Invazivni mykoticke infekce u imunokompromitovanych nemocnych se zamerenim na aspergilozu a jeji puvodce. KLINICKA MIKROBIOLOGIE A INFEKCNI LEKARSTVI 18, p. 96 - 101
• ADAM, Z.;P. SZTURZ;J. DURAS;L. POUR;M. KREJCI;Z. REHAK;R. KOUKALOVA;M. NAVRATIL;R. HAJEK;Z. KRAL;J. MAYER., 2012: Lecba histiocytozy z Langerhansovych bunek kladribinem dosahla u 9 z 10 dospelych pacientu dlouhodobe kompletni remise. KLINICKA ONKOLOGIE 25, p. 255 - 261
• ADAM, Z.;Z. REHAK;R. KOUKALOVA;P. SZTURZ;M. KREJCI;L. POUR;L. ZAHRADOVA;M. MOULIS;R. KODET;T. NEBESKY;M. BREJCHA;Z. ADAMOVA;R. HAJEK;J. MAYER., 2012: Lenalidomid indukoval lecebnou odpoved u pacienta s agresivni multisystemovou formou histiocytozy z Langerhansovych bunek (LCH), rezistentni ke 2-chlorodeoxyadenosinu a casne relabujici po vysokodavkovane chemoterapii. VNITRNI LEKARSTVI 58, p. 62 - 71
• Malaskova, L; Winterova, J; Dastych, M; Racil, Z; Kocmanova, I; Toskova, M; Mayer, J, 2012: Parallel Determination of Voriconazole and Posaconazole in Plasma by HPLC. CHEMICKE LISTY 106(7), p. 677 - 680
• ADAM, Z.;K. VESELY;I. MOTYCKOVA;P. SZTURZ;R. KOUKALOVA;Z. REHAK;J. STOURACOVA;J. VANICEK;M. KREJCI;L. POUR;L. ZAHRADOVA;R. HAJEK;Z. KRAL;J. MAYER., 2012: Ocni vicka se zlutymi granulomy a kasel - periokularni xanthogranulom dospelych spojeny s astmatem. Popis pripadu a prehled klinickych forem juvenilniho xantogranulomu a terapie. VNITRNI LEKARSTVI 58, p. 365 - 377
• SZTURZ, P.;Z. ADAM;M. MOULIS;L. SMARDOVA;M. KLINCOVA;R. SLAISOVA;R. KOUKALOVA;Z. REHAK;P. VOLFOVA;J. CHOVANCOVA;O. STEHLIKOVA;J. MAYER., 2012: Nase zkusenosti s lecbou multicentricke plazmocelularni Castlemanovy choroby s projevy vaskulitidy – popis pripadu a prehled literatury. VNITRNI LEKARSTVI 58, p. 679 - 690
• RACIL, Z.;J. WINTEROVA;M. KOUBA;P. ZAK;L. MALASKOVA;L. BURESOVA;M. TOSKOVA;M. LENGEROVA;I. KOCMANOVA;B. WEINBERGEROVA;S. TIMILSINA;M. ROLENCOVA;P. CETKOVSKY;J. MAYER., 2012: Monitoring through voriconazole plasma concentrations in haematological patients: real life multicentre experience. MYCOSES 55, p. 483 - 492
• Szturz, P; Rehak, Z; Koukalova, R; Adam, Z; Krejci, M; Pour, L; Zahradova, L; Vanicek, J; Nebesky, T; Hajek, R; Mayer, J, 2012: Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. NUCLEAR MEDICINE AND BIOLOGY 39(3), p. 429 - 436, doi: 10.1016/j.nucmedbio.2011.10.002
• Szturz, P; Adam, Z; Chovancova, J; Stehlikova, O; Klabusay, M; Rehak, Z; Koukalova, R; Krejci, M; Pour, L; Zahradova, L; Hajek, R; Mayer, J, 2012: Lenalidomide: a new treatment option for Castleman disease. LEUKEMIA & LYMPHOMA 53(10), p. 2089 - 2091, doi: 10.3109/10428194.2011.621564
• Szturz, P; Adam, Z; Rehak, Z; Koukalova, R; Slaisova, R; Stehlikova, O; Chovancova, J; Klabusay, M; Krejci, M; Pour, L; Hajek, R; Mayer, J, 2012: Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. ACTA ONCOLOGICA 51(3), p. 412 - U148, doi: 10.3109/0284186X.2011.631581
• Racil, Z; Winterova, J; Kouba, M; Zak, P; Malaskova, L; Buresova, L; Toskova, M; Lengerova, M; Kocmanova, I; Weinbergerova, B; Timilsina, S; Rolencova, M; Cetkovsky, P; Mayer, J, 2012: Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. MYCOSES 55(6), p. 483 - 492, doi: 10.1111/j.1439-0507.2012.02186.x
• Simara, P; Peterkova, M; Stejskal, S; Potesilova, M; Koutna, I; Racil, Z; Razga, F; Jurcek, T; Dvorakova, D; Mayer, J, 2012: BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. LEUKEMIA & LYMPHOMA 53(8), p. 1627 - 1629, doi: 10.3109/10428194.2012.656104
• Volfova, P; Lengerova, M; Winterova, J; Racil, Z; Dvorakova, D; Mayer, J, 2012: Monitoring of Epstein-Barr virus load in patients after allogeneic hematopoietic stem cell transplantation. INFECTION 40(5), p. 583 - 587, doi: 10.1007/s15010-012-0262-5
• Lengerova, M; Kocmanova, I; Racil, Z; Hrncirova, K; Pospisilova, S; Mayer, J; Najvar, LK; Wiederhold, NP; Kirkpatrick, WR; Patterson, TF, 2012: Detection and Measurement of Fungal Burden in a Guinea Pig Model of Invasive Pulmonary Aspergillosis by Novel Quantitative Nested Real-Time PCR Compared with Galactomannan and (1,3)-beta-D-Glucan Detection. JOURNAL OF CLINICAL MICROBIOLOGY 50(3), p. 602 - 608, doi: 10.1128/JCM.05356-11
• Guilhot, J; Baccarani, M; Clark, RE; Cervantes, F; Guilhot, F; Hochhaus, A; Kulikov, S; Mayer, J; Petzer, AL; Rosti, G; Rousselot, P; Saglio, G; Saussele, S; Simonsson, B; Steegmann, JL; Zaritskey, A; Hehlmann, R, 2012: Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. BLOOD 119(25), p. 5963 - 5971, doi: 10.1182/blood-2011-10-383711
• Kozubik, KS; Malcikova, J; Trbusek, M; Tom, N; Doubek, M; Brychtova, Y; Smardova, J; Mayer, J; Pospisilova, S; Tichy, B, 2012: Clonal Selection of TP53 Mutations in Chronic Lymphocytic Leukaemia Detected by Ultra-deep Pyrosequencing. EUROPEAN JOURNAL OF CANCER 48, p. S146 - S146
• Panovska, A; Lysak, D; Smolej, L; Brychtova, Y; Simkovic, M; Motyckova, M; Lindtnerova, M; Trbusek, M; Malcikova, J; Pospisilova, S; Mayer, J; Doubek, M, 2012: The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. BLOOD 120(21)
• Zemanova, J; Sebejova, L; Hylse, O; Paruch, K; Pavlova, S; Mayer, J; Pospisilova, S; Trbusek, M, 2012: Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 Mutations to Chemotherapy. BLOOD 120(21)

2011

• Socie, G; Schmoor, C; Bethge, WA; Ottinger, HD; Stelljes, M; Zander, AR; Volin, L; Ruutu, T; Heim, DA; Schwerdtfeger, R; Kolbe, K; Mayer, J; Maertens, JA; Linkesch, W; Holler, E; Koza, V; Bornhauser, M; Einsele, H; Kolb, HJ; Bertz, H; Egger, M; Grishina, , 2011: Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. BLOOD 117(23), p. 6375 - 6382, doi: 10.1182/blood-2011-01-329821
• Pavlik, T; Janousova, E; Pospisil, Z; Muzik, J; Zackova, D; Racil, Z; Klamova, H; Cetkovsky, P; Trneny, M; Mayer, J; Dusek, L, 2011: Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. BMC MEDICAL RESEARCH METHODOLOGY 11, doi: 10.1186/1471-2288-11-140
• Trbusek, M; Smardova, J; Malcikova, J; Sebejova, L; Dobes, P; Svitakova, M; Vranova, V; Mraz, M; Francova, HS; Doubek, M; Brychtova, Y; Kuglik, P; Pospisilova, S; Mayer, J, 2011: Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia. JOURNAL OF CLINICAL ONCOLOGY 29(19), p. 2703 - 2708, doi: 10.1200/JCO.2011.34.7872
• Coiffier, B; Osmanov, EA; Hong, XN; Scheliga, A; Mayer, J; Offner, F; Rule, S; Teixeira, A; Walewski, J; de Vos, S; Crump, M; Shpilberg, O; Esseltine, DL; Zhu, E; Enny, C; Theocharous, P; van de Velde, H; Elsayed, YA; Zinzani, PL, 2011: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. LANCET ONCOLOGY 12(8), p. 773 - 784, doi: 10.1016/S1470-2045(11)70150-4
• Racil, Z; Buresova, L; Brejcha, M; Prochazkova, J; Zounar, R; Timilsina, S; Razga, F; Toskova, M; Cetkovsky, P; Mayer, J, 2011: Clinical and laboratory features of leukemias at the time of diagnosis: An analysis of 1,004 consecutive patients. AMERICAN JOURNAL OF HEMATOLOGY 86(9), p. 800 - 803, doi: 10.1002/ajh.22100
• Doubek, M; Mayer, J; Obrtlikova, P; Smolej, L; Cmunt, E; Schwarz, J; Brejcha, M; Kozmon, P; Pospisilova, S; Brychtova, Y; Pospisil, Z; Trneny, M, 2011: Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. EUROPEAN JOURNAL OF HAEMATOLOGY 87(2), p. 130 - 137, doi: 10.1111/j.1600-0609.2011.01639.x
• Krejci, M; Brychtova, Y; Doubek, M; Tomiska, M; Navratil, M; Racil, Z; Dvorakova, D; Horky, O; Lengerova, M; Pospisilova, S; Mayer, J, 2011: Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. NEOPLASMA 58(5), p. 406 - 414, doi: 10.4149/neo_2011_05_406
• Basak, GW; Jaksic, O; Koristek, Z; Mikala, G; Mayer, J; Masszi, T; Labar, B; Wiktor-Jedrzejczak, W, 2011: Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. AMERICAN JOURNAL OF HEMATOLOGY 86(7), p. 550 - 553, doi: 10.1002/ajh.22038
• Szturz, P; Adam, Z; Klincova, M; Feit, J; Krejci, M; Pour, L; Zahradova, L; Vasku, V; Hajek, R; Mayer, J, 2011: Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 11(6), p. 517 - 520, doi: 10.1016/j.clml.2011.06.014
• Racil, Z; Kocmanova, I; Toskova, M; Buresova, L; Weinbergerova, B; Lengerova, M; Rolencova, M; Winterova, J; Hrncirova, K; Volfova, P; Skrickova, J; Mayer, J, 2011: Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 15(12), p. E874 - E881, doi: 10.1016/j.ijid.2011.09.011
• Walewski, J; Paszkiewicz-Kozik, E; Warszewska, A; Borsaru, G; Moicean, A; Hellmann, A; Mayer, J; Hauns, B; Mais, A; Henning, SW; Hentsch, B, 2011: Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma. BLOOD 118(21), p. 1149 - 1149
• Fiegl, M; Falkner, F; Steurer, M; Zojer, N; Hopfinger, G; Haslbauer, F; Winder, G; Voskova, D; Andel, J; Lang, A; Brychtova, Y; Mayer, J; Greil, R; Gastl, G, 2011: Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. ANNALS OF HEMATOLOGY 90(9), p. 1083 - 1091, doi: 10.1007/s00277-011-1192-5
• Krejci, M; Gregora, E; Straub, J; Minarik, J; Scudla, V; Adam, Z; Krivanova, A; Pour, L; Zahradova, L; Buchler, T; Mayer, J; Hajek, R, 2011: Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. ANNALS OF HEMATOLOGY 90(12), p. 1441 - 1447, doi: 10.1007/s00277-011-1206-3
• Trbusek, M; Malcikova, J; Mayer, J, 2011: Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia. LEUKEMIA RESEARCH 35(7), p. 981 - 982, doi: 10.1016/j.leukres.2011.02.005
• Mocikova, H; Pytlik, R; Markova, J; Steinerova, K; Kral, Z; Belada, D; Trnkova, M; Trneny, M; Koza, V; Mayer, J; Zak, P; Kozak, T, 2011: Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. LEUKEMIA & LYMPHOMA 52(9), p. 1668 - 1674, doi: 10.3109/10428194.2011.573889
• Razga, F; Racil, Z; Polakova, KM; Buresova, L; Klamova, H; Zackova, D; Dvorakova, D; Polivkova, V; Cetkovsky, P; Mayer, J, 2011: The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. INTERNATIONAL JOURNAL OF HEMATOLOGY 94(3), p. 303 - 306, doi: 10.1007/s12185-011-0924-6
• Basak, GW; Mikala, G; Koristek, Z; Jaksic, O; Basic-Kinda, S; Cegledi, A; Reti, M; Masszi, T; Mayer, J; Giebel, S; Hubel, K; Labar, B; Wiktor-Jedrzejczak, W, 2011: Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it´s not too late. LEUKEMIA & LYMPHOMA 52(9), p. 1711 - 1719, doi: 10.3109/10428194.2011.578312

2010

• Kotaskova, Jana; Tichy, Boris; Trbusek, Martin; Francova, Hana Skuhrova; Kabathova, Jitka; Malcikova, Jitka; Doubek, Michael; Brychtova, Yvona; Mayer, Jiri; Pospisilova, Sarka, 2010: High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated lmmunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival. JOURNAL OF MOLECULAR DIAGNOSTICS 12(3), p. 328 - 334, doi: 10.2353/jmoldx.2010.090100
• Malcikova, J; Tichy, B; Damborsky, J; Kabathova, J; Trbusek, M; Mayer, J; Pospisilova, S, 2010: Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation. BIOLOGICAL CHEMISTRY 391(2 III), p. 197 - 205, doi: 10.1515/BC.2010.027
• Giebel, S; Stella-Holowiecka, B; Krawczyk-Kulis, M; Gokbuget, N; Hoelzer, D; Doubek, M; Mayer, J; Piatkowska-Jakubas, B; Skotnicki, AB; Dombret, H; Ribera, JM; Piccaluga, PP; Czerw, T; Kyrcz-Krzemien, S; Holowiecki, J, 2010: Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. BONE MARROW TRANSPLANTATION 45(6), p. 1095 - 1101, doi: 10.1038/bmt.2009.308
• Hallek, M; Fischer, K; Fingerle-Rowson, G; Fink, AM; Busch, R; Mayer, J; Hensel, M; Hopfinger, G; Hess, G; von Grunhagen, U; Bergmann, M; Catalano, J; Zinzani, PL; Caligaris-Cappio, F; Seymour, JF; Berrebi, A; Jager, U; Cazin, B; Trneny, M; Westermann, A; Wendtner, CM; Eichhorst, BF; Staib, P; Buhler, A; Winkler, D; Zenz, T; Bottcher, S; Ritgen, M; Mendila, M; Kneba, M; Dohner, H; Stilgenbauer, S, 2010: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. LANCET 376(9747), p. 1164 - 1174, doi: 10.1016/S0140-6736(10)61381-5
• Kantarjian, H; Shah, NP; Hochhaus, A; Cortes, J; Shah, S; Ayala, M; Moiraghi, B; Shen, ZX; Mayer, J; Pasquini, R; Nakamae, H; Huguet, F; Boque, C; Chuah, C; Bleickardt, E; Bradley-Garelik, MB; Zhu, C; Szatrowski, T; Shapiro, D; Baccarani, M, 2010: Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. NEW ENGLAND JOURNAL OF MEDICINE 362(24), p. 2260 - 2270, doi: 10.1056/NEJMoa1002315
• Zenz, T; Vollmer, D; Trbusek, M; Smardova, J; Benner, A; Soussi, T; Helfrich, H; Heuberger, M; Hoth, P; Fuge, M; Denzel, T; Habe, S; Malcikova, J; Kuglik, P; Truong, S; Patten, N; Wu, L; Oscier, D; Ibbotson, R; Gardiner, A; Tracy, I; Lin, K; Pettitt, A; Pospisilova, S; Mayer, J; Hallek, M; Dohner, H; Stilgenbauer, S, 2010: TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. LEUKEMIA 24(12), p. 2072 - 2079, doi: 10.1038/leu.2010.208
• Fiegl, M; Erdel, M; Tinhofer, I; Brychtova, Y; Panovska, A; Doubek, M; Eigenberger, K; Fonatsch, C; Hopfinger, G; Muhlberger, H; Zabernigg, A; Falkner, F; Gastl, G; Mayer, J; Greil, R, 2010: Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. ANNALS OF ONCOLOGY 21(12), p. 2410 - 2419, doi: 10.1093/annonc/mdq236

2009

• CEJKOVA, S., ROCNOVA, L., POTESIL, D., SMARDOVA, J., NOVAKOVA, V., CHUMCHALOVA, J., ZEZULKOVA, D., BORSKY, M., DOUBEK, M., BRYCHTOVA, Y., POSPISILOVA, S., KLABUSAY, M., MAYER, K., TRBUSEK, M., 2009: Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. EUROPEAN JOURNAL OF HAEMATOLOGY , p. 133 - 142
• MALCIKOVA, J., SMARDOVA, J., ROCNOVA, L., TICHY, B., KUGLIK, P., VRANOVA, V., CEJKOVA, S., SVITAKOVA, M., SKUHROVA FRANCOVA, H., BRYCHTOVA, Y., DOUBEK, M., BREJCHA, M., KLABUSAY, M., MAYER, J., POSPISILOVA, S., TRBUSEK, M., 2009: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. BLOOD 114(26), p. 5307 - 5314
• MRAZ, M., MALINOVA, K., KOTASKOVA, J., PAVLOVA, S., TICHY, B., MALCIKOVA, J., STANO-KOZUBIK, K., SMARDOVA, J., BRYCHTOVA, Y., DOUBEK, M., TRBUSEK, M., MAYER, J., POSPISILOVA, S., 2009: miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. LEUKEMIA 23(6), p. 1159 - 1163

• Expression and function of activation-induced cytidine deaminase splice variants in normal B cell physiology and chronic lymphocytic leukemia (3SGA5792), Jihomoravský kraj, 2013 - 2016
• Functional and structural changes of microRNAs in lymphoproliferative malignancies and their impact on prognosis and prediction of therapy response (NT11218), Ministry of Health - Ministry of Health´s Departmental Research and Development Programme III (2010-2015), 2010 - 2015
• Funkční a strukturní změny microRNA u lymfoproliferativních malignit a jejich vliv na prognózu onemocnění a predikci léčebné odpovědi, Ministry of Health of the CR, 2010 - 2015
• NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (306242), Evropská unie, 2012 - 2015
• SuPReMMe - Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny (CZ.1.07/2.3.00/20.0045), Ministerstvo školství, mládeže a tělovýchovy ČR, 2011 - 2014
• Real-time PCR soupravy pro diagnostiku v onkologii (FR-TI2/254), Ministerstvo průmyslu a obchodu ČR, 2010 - 2013
• Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies (MSM0021622430), Ministerstvo školství, mládeže a tělovýchovy ČR, 2007 - 2013
• Involvement of nuclear HMGB proteins in sensitizing of human cells to anticancer drugs inhibiting DNA topoizomerases (GAP301/10/0590), Czech Science Foundation - Standard Grants, 2010 - 2012
• Analysis of changes in genome and its expression in chronic lymphocytic leukemia patients during the disease development (NS10439), Ministry of Health - Departmental Programme of Research and Development (2008-2011), 2009 - 2011